-
公开(公告)号：KR101258652B1
公开(公告)日：2013-04-29
申请号：KR1020110018962
申请日：2011-03-03
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 크기 배제 크로마토그래피 방법(size exclusion high performance liquid chromatography, SE-HPLC)을 이용하여 표준항원과 표준항체가 없어도 인플루엔자 백신의 헤마글루티닌의 정량을 가능하게 한 방법으로, 기존에 인플루엔자 백신의 헤마글루티닌을 정량하는 방법인 방사면역확산법(single radial immunodiffusion technique, SRID)보다 헤마글루티닌의 농도를 확인하는 시간이 현저하게 단축되었으면서도 정량 정확도는 더 높아진 헤마글루티닌의 정량 방법이다.
-
公开(公告)号：KR1020110131630A
公开(公告)日：2011-12-07
申请号：KR1020100051165
申请日：2010-05-31
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6865 , C12Q2600/156 , C12Q2600/172
Abstract: PURPOSE: A haplotype analysis kit of NAT2 gene promoter and an analysis method using the same are provided to analyze genetic polymorphism of NAT2 and to develop a drug. CONSTITUTION: A method for analyzing haplotype of human NAT2 gene comprises: a step of performing PCR of genome DNA of a test person using a primer set for amplifying the human NAT2 gene promoter or fragment of the fragment; a step of analyzing base sequence of DNA product prepared by PCR; a step of determining SNP presence of -10818 T>C(2942th base of sequence number 8), -10065 A>G(3695th base of sequence number 8), -9905 T>C(3855th base of sequence number 8), -9601 A>G(4159th base of sequence number 8), -9246 G>C(4514th base of sequence number 8), or -8853 A>G(4907th base of sequence number 8).
Abstract translation: 目的：提供NAT2基因启动子的单倍型分析试剂盒及其分析方法，分析NAT2的遗传多态性，开发药物。 构成：用于分析人类NAT2基因单倍型的方法包括：使用引物组进行测试人基因组DNA的PCR扩增步骤，以扩增人类NAT2基因启动子或片段片段; 分析通过PCR制备的DNA产物碱基序列的步骤; 确定天然存在的步骤（序列号8的第2942个碱基），-10065A> G（序列号8的第3695位），-9905T> C（序列号8的第3855位）的SNP存在的步骤， （序列号815的第4159位），-9246G> C（序列号845的第4514位）或-8853A> G（序列号890的第497位）。
-
公开(公告)号：KR1020130060835A
公开(公告)日：2013-06-10
申请号：KR1020110127108
申请日：2011-11-30
Applicant: 대한민국 (식품의약품안전처장) , 경희대학교 산학협력단 , 서울대학교산학협력단
IPC: A61K31/7048 , A61K31/70 , A61P25/28
CPC classification number: A61K31/7048 , A23L2/52 , A23L33/10 , A23L33/135 , A23V2002/00 , A61K36/185 , A61K36/42 , A61K36/47 , A61K36/48 , A61K36/725
Abstract: PURPOSE: A pharmaceutical composition containing spinosin or a spinosin-containing crude drug extract is provided to effectively improve memory and learning ability and to effectively prevent and treat cognitive disorders such as dementia and amnesia. CONSTITUTION: A composition for preventing or treating cognitive disorder contains spinosin. The composition also contains one or more extracts selected from a group consisting of Zizyphus jujuba Mill var. inermis, Zizyphus jujuba Mill var. hoonensis, Zizyphus jujuba Mill var. spinosa, Passiflora edulis flavicarpa, Cayaponia tayuya, Desmodium tortuosum, Wilbrandia ebracteata, Strophioblachia fimbricalyx, Clutia abyssinica, and Saccharopolyspora spinosa. The cognitive disorders are dementia or amnesia. A food composition for preventing or treating cognitive disorders contains spinosin. [Reference numerals] (AA) Delay time(seconds); (BB) In the middle of learning; (CC) In the middle of the present experiment; (DD) Control group 3; (EE) Control group 2; (FF) Medicine injected group 1; (GG) Medicine injected group 2; (HH) Medicine injected group 3; (II) Medicine injected group 4; (JJ) Control group 1
Abstract translation: 目的：提供含有刺糖苷或含刺糖苷的生药提取物的药物组合物，有效提高记忆力和学习能力，有效预防和治疗认知障碍，如痴呆和遗忘症。 构成：用于预防或治疗认知障碍的组合物含有刺糖苷。 该组合物还含有一种或多种提取物，选自Zizyphus jujuba Mill var。 Z hus枣 枣树，枣树 菠萝，西番莲，洋葱，Cataaponia tayuya，枸杞，Wilbrandia ebracteata，Strophioblachia fimbricalyx，黑蛤和Saccharopolyspora spinosa。 认知障碍是痴呆或遗忘症。 用于预防或治疗认知障碍的食物组合物含有刺糖苷。 （附图标记）（AA）延迟时间（秒）; （BB）在学习的中间; （CC）在本实验中期; （DD）对照组3; （EE）对照组2; （FF）药物注射组1; （GG）药物注射组2; （HH）药物注射组3; （二）药物注射组4; （JJ）对照组1
-
公开(公告)号：KR1020110133223A
公开(公告)日：2011-12-12
申请号：KR1020100052835
申请日：2010-06-04
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12N9/00 , C12Q1/26 , C12Q1/6844 , C12Q2600/172
Abstract: PURPOSE: A method for predicting DPD(Dihydropyrimidine dehydrogenase) is provided to analyze genetic polymorphism of DPD and to develop a drug metabolized by DPD. CONSTITUTION: A method for analysis of Korean DPD gene haplotype comprises: a step of obtaining exon 13 and intron 13 encoding DPD from genome DNA to determine each base sequence; a step of detecting SNP in the determined each base sequence; and a step of identifying haplotype selected among Hap1 to Hap3 using the detected SNP. A method for predicting Korean DPD comprises: a step of confirming a DPD gene of a person who is tested, among Hap1 to Hap3; and a step of predicting DPD activity using the confirmed haplotype information.
Abstract translation: 目的：提供一种预测DPD（二氢嘧啶脱氢酶）的方法，用于分析DPD的遗传多态性并开发DPD代谢的药物。 构成：分析韩国DPD基因单体型的方法包括：从基因组DNA获得编码DPD的外显子13和内含子13以确定每个碱基序列的步骤; 检测确定的每个碱基序列中的SNP的步骤; 以及使用检测到的SNP鉴定从Hap1至Hap3中选择的单元型的步骤。 用于预测韩国DPD的方法包括：在Hap1至Hap3中确认被测试人的DPD基因的步骤; 以及使用确认的单元型信息来预测DPD活性的步骤。
-
公开(公告)号：KR100332485B1
公开(公告)日：2002-04-15
申请号：KR1020000007988
申请日：2000-02-19
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 마황 추출물의 새로운 의학적 용도에 관한 것으로, 구체적으로 마황의 물 추출물, 그 건조 분말 또는 이를 물에 녹인 후 원심분리하여 얻은 수용성 분획을 유효성분으로 하는 B형 간염 치료제에 관한 것이다. 본 발명의 마황 추출물은 아직까지 안정성과 유효성이 우수한 치료제가 없는 HBV 감염 치료제 분야에서 탁월한 효과를 나타내며, 독성 또한 기존에 알려진 화합물보다 월등히 낮고, 제조 공정 또한 매우 간단하여 경제적이고 효과적인 B형 간염 바이러스 감염 치료제로 사용될 수 있다.
-
Patent Agency Ranking
公开(公告)号：KR101315255B1
公开(公告)日：2013-10-08
申请号：KR1020100051165
申请日：2010-05-31
Applicant: 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 NAT2를 암호화하는 유전자의 프로모터 부위내에 위치한 단일염기다형성(SNP)로부터 특정 일배체형(Haplotype)을 결정하였으며, 이 특정 일배체형(Haplotype)을 분석할 수 있는 상기 유전자 프로모터의 증폭용 프라이머를 포함하는 NAT2 유전자 프로모터의 일배체형 분석키트 및 이를 이용한 분석방법에 관한 것이다. 본 발명에 의하면, 개인간 유전형의 차이에 따른 맞춤의약을 포함하여,
NAT2 에 의하여 대사되는 약물의 개발에 널리 활용될 수 있다.-
公开(公告)号：KR1020130102778A
公开(公告)日：2013-09-23
申请号：KR1020120023880
申请日：2012-03-08
Applicant: 대한민국 (식품의약품안전처장)
CPC classification number: C12Q1/6827 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/15 , G01N2800/52
Abstract: PURPOSE: A method for predicting drug response to atomoxetine using the genotype of cytochrome P450 2D6 (CYP2D6) gene is provided to compute a recommended dosage of a drug by each genotype, thereby presenting a proposal on drug approvals in consideration of Korean pharmacogenomics. CONSTITUTION: A method for analyzing the genotype of CYP2D6 gene for predicting drug response to atomoxetine comprises the step of sequencing exon 1 and exon 6 of a gene encoding CYP2D6 from a genomic DNA; detecting single nucleotide polymorphisms (SNPs) in the determined base sequence, wherein 43th base (T) of sequence number 1 (exon 6) is substituted with C (CYP2D6*2) and 100th base (C) of sequence number 2 (exon 1) is substituted with T (CYP2D6*10); and determining if the genotype of CYP2D6 belongs to extensive metabolizer (CYP2D6EM), intermediate metabolizer (CYP2D6IM), or poor metabolizer (CYP2D6PM). [Reference numerals] (AA) Atomoxetine (ng/mL); (BB) Elapse time after injection (hr)
Abstract translation: 目的：提供使用细胞色素P450 2D6（CYP2D6）基因的基因型预测药物对阿托西汀药物反应的方法，以计算每种基因型药物的推荐剂量，从而提出考虑韩国药物基因组学的药物批准建议。 构成：分析CYP2D6基因基因型预测阿托西汀药物反应的方法，包括从基因组DNA测序编码CYP2D6基因的外显子1和外显子6的步骤; 检测确定的碱基序列中的单核苷酸多态性（SNP），其中序列号1（外显子6）的第43位碱基（T）被C（CYP2D6 * 2）和序列号2（外显子1）的第100位碱基（C） 被T（CYP2D6 * 10）取代; 并确定CYP2D6的基因型是否属于广泛代谢者（CYP2D6EM），中间代谢者（CYP2D6IM）或低代谢者（CYP2D6PM）。 （标号）（AA）阿托莫西汀（ng / mL）; （BB）注射后经过时间（小时）
-
公开(公告)号：KR1020130021764A
公开(公告)日：2013-03-06
申请号：KR1020110084225
申请日：2011-08-23
Applicant: 경희대학교 산학협력단 , 대한민국 (식품의약품안전처장)
Abstract: PURPOSE: An intestinal microbial enzyme complex and a method for preparing the same are provided to ensure anti-allergic, anti-inflammatory, anticancer, and anti-aging effects in vitro. CONSTITUTION: An intestinal microbial enzyme complex contains Megasphaera elsdenii, Parabacteroides distasonis, Klebsiella pneumoniae, and Eubacterium rectale in a ratio of 1:1:1:1. The complex has an enzyme activity to one or more substrates selected from the group consisting of p-nitrophenyl-beta-Dglucuronide, p-nitrophenyl-beta-D-xylopyranoside, nitrophenyl-alpha-L-rhamnopyranoside, and pnitrophenyl-beta-D-glucopyranoside.
Abstract translation: 目的：提供肠微生物酶复合物及其制备方法，以确保体外抗过敏，抗炎，抗癌和抗衰老作用。 构成：肠微生物酶复合物以1:1:1:1的比例含有Megasphaera elsdenii，Parabacteroides distasonis，肺炎克雷伯杆菌和直肠杆菌。 该复合物对一种或多种选自对硝基苯基-β-葡萄糖醛酸苷，对硝基苯基-β-D-吡喃木糖苷，硝基苯基-α-L-鼠李糖吡喃糖苷和对硝基苯基-β- 吡喃葡萄糖苷。
-
公开(公告)号：KR1020120100214A
公开(公告)日：2012-09-12
申请号：KR1020110018962
申请日：2011-03-03
Applicant: 대한민국 (식품의약품안전처장)
Abstract: PURPOSE: A quantitative analysis of hemagglutinin of influenza vaccine is provided to quantifying the hemagglutinin of influenza vaccine without standard antigen and standard antibody. CONSTITUTION: A quantitative analysis of hemagglutinin of influenza vaccine comprises the following steps: separating a standard antigen the concentration in which hemagglutinin concentration is known by using the size exclusion chromatography; separating influenza vaccines in which the hemagglutinin concentration is not know by using the size exclusion chromatography under the same condition as the first step; calculating area of peaks which show the antigen-antibody reactions by using the result of the size exclusion chromatography of the standard antigen in the first step; calculating the area of peaks corresponding to the peaks in the third step by using the size exclusion chromatography result of the influenza vaccine; multiplying by the hemagglutinin return concentration of the standard antigen in the first step after dividing the outcome of the fourth step into the outcome of the third step; and calculating concentration correcting value which is the difference of converted value of each peak area, in which the antigen-antibody reaction is displayed based on 1 micro gram of hemagglutinin performing the size exclusion chromatography is using the standard antigen provided in the first step and performing the size exclusion chromatography by using the influenza vaccine which can checks the concentration of the hemagglutinin; and dividing the result of the fifth step by the concentration correction value of the hemagglutinin of the influenza vaccine in the sixth step.
Abstract translation: 目的：提供流感疫苗血凝素的定量分析，以量化没有标准抗原和标准抗体的流感疫苗血凝素。 构成：流感疫苗血凝素的定量分析包括以下步骤：使用尺寸排阻色谱法分离标准抗原血凝素浓度的浓度; 通过在与第一步相同的条件下使用尺寸排阻色谱法分离其中血凝素浓度不知道的流感疫苗; 通过使用第一步中标准抗原的大小排阻色谱的结果计算显示抗原 - 抗体反应的峰的面积; 通过使用流感疫苗的大小排阻色谱结果计算与第三步骤中的峰对应的峰的面积; 在将第四步骤的结果除以第三步骤的结果之后，将标准抗原的血凝素返回浓度乘以第一步骤; 并且基于进行大小排阻色谱的1微克血凝素显示出其中显示抗原 - 抗体反应的每个峰面积的转化值的差异的浓度校正值是使用第一步中提供的标准抗原，并进行 通过使用可以检查血凝素浓度的流感疫苗的大小排阻色谱法; 并且将第五步骤的结果除以流感疫苗的血细胞凝集素的浓度校正值。
-
公开(公告)号：KR100387279B1
公开(公告)日：2003-06-12
申请号：KR1020000079495
申请日：2000-12-21
Applicant: 대한민국 (식품의약품안전처장) , 대한민국(관리부서 : 산림청 국립산림과학원장)
IPC: A61K36/896
Abstract: PURPOSE: A pharmaceutical composition containing an Allium victorialis var. platyphyllum extract having a therapeutic and preventing activity against arteriosclerosis as an effective component is provided which can be effectively used as a pharmaceutical component and an effective component of functional food for prevention and treatment of arteriosclerosis and hypercholesterolemia. CONSTITUTION: A dried Allium victorialis var. platyphyllum is ground to 20 to 100 mesh, mixed 2 to 5 times with ethanol and extracted at 15 to 50deg.C for 24 to 96 hr. The extract remarkably reduces the amount of cholesterol and lipid peroxide in blood and has an inhibition activity on cholesteryl ester transfer protein enzyme for transferring HDL cholesterol to arteriosclerosis-inducing low density lipoprotein cholesterol.
Abstract translation: 目的：一种含有葱属植物变种的药物组合物。 提供具有针对动脉硬化的治疗和预防活性的扁桃酚提取物作为有效成分，其可以有效地用作用于预防和治疗动脉硬化和高胆固醇血症的功能性食品的药物成分和有效成分。 组成：干韭菜var。 将Platyphyllum粉碎至20至100目，用乙醇混合2至5次，并在15至50℃提取24至96小时。 该提取物显着降低血液中胆固醇和脂质过氧化物的量，并且对胆固醇酯转移蛋白酶具有抑制活性，用于将HDL胆固醇转化为诱导动脉硬化的低密度脂蛋白胆固醇。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.032 seconds)
